2 results about "Tumor vessel" patented technology

The present application relates to the technical field of biological medicine, and particularly relates to application of SHLA in preparation of a glioblastoma chemotherapy sensitizer.SHLA is a high-affinity leptin antagonist, which can block the JAK / STAT3, p38-MAPK and other signal pathways mediated by leptin.In a human GBM cell line orthotopic xenograft mouse model, under the premise of not affecting tumor vascular endothelial cells, SHLA significantly reduces the coverage of tumor pericytes, thereby destroying the "blood-tumor barrier" of glioblastoma and increasing the permeability of the "blood-tumor barrier", and improving the concentration of chemotherapeutic drugs in tumor tissues, thereby playing a chemotherapy sensitization role.SHLA has no serious side effects on non-targeted main organs, has no effect on the "blood-brain barrier", and has good safety.

The application belongs to the technical field of biological medicine, and discloses a tumor local acute inflammation inducer, a preparation method and application thereof. Specifically, extracted bacterial outer membrane vesicles are loaded into prepared temperature-sensitive hydrogel for in-situ injection treatment of common clinical solid tumors, such as breast cancer, melanoma, colorectal cancer and the like. The temperature-sensitive hydrogel loaded with bacterial outer membrane vesicles constructed in the application induces acute inflammation at the tumor site, effectively activates anti-tumor immunity, and improves the immunosuppressive microenvironment; at the same time, the temperature-sensitive hydrogel causes rupture of tumor blood vessels, and can be combined with photothermal therapy to further eradicate tumors; and the temperature-sensitive hydrogel limits acute inflammation in the tumor, improves biological safety, and provides a new strategy for development of in-situ tumor treatment preparations.